The discovery of SETD2 as a frequently mutated gene in phyllodes tumors of the breast (PT) suggests SETD2 may serve as a biomarker for this aggressive breast cancer subtype [130]. The gene discussed is SETD2; the disease is breast phyllodes tumor.